78% of Life Science Teams Conducting Phase 4 Research Turn to Medical Affairs Teams for Post-Marketing Activities
30 mai 2017 20h09 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - May 30, 2017) - Approximately 78% of surveyed life science teams with dedicated post-marketing groups align them under medical affairs, according to new...
Roughly 82% of Pharma Companies Conduct Observational Studies Each Year
27 avr. 2017 09h30 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - April 27, 2017) - The majority (82%) of surveyed drug manufacturers reported conducting -- or planning to conduct -- observational studies last year, which...
Planning Phase 4 Studies: When (and Where) to Involve Medical Affairs Teams
15 févr. 2017 08h08 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - February 15, 2017) - Global pharmaceutical businesses are the most likely to involve multiple functions in postmarketing, or Phase 4, study planning. A...
Phase 4 Pharmaceutical Studies Lean on Medical Affairs for Strategic Planning
29 nov. 2016 08h17 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - November 29, 2016) - Medical affairs functions are an ideal candidate to head post-marketing study strategy, according to new research published by...
70% of Pharmaceutical Companies Have a Global Level Phase 4 Groups
31 août 2016 07h42 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - August 31, 2016) - A new study published by Cutting Edge Information reported that 70% of surveyed pharmaceutical firms employ Phase 4 groups at the global...
Fifty-One Percent of All US Post-Marketing Studies are Commitment Trials
17 août 2016 07h22 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - August 17, 2016) - A new study published by Cutting Edge Information found that on average, just over half of all US studies are commitment studies as...
78% of Pharma Medical Affairs Teams Continue to Support Post-Marketing Studies
08 août 2016 07h43 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - August 08, 2016) - New data published by Cutting Edge Information reveal that the majority of surveyed pharmaceutical companies continue to support...
Top 10 Global Pharma Company Reports a 3 Million Dollar Increase in Post-Marketing Study Investments
19 juil. 2016 08h17 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - July 19, 2016) - A new study published by Cutting Edge Information found that at least one Top 10 pharmaceutical company grew its post-marketing study...
Drug Companies Spend an Average $13,000 per Patient on Comparative Effectiveness Research in Phase IV
09 août 2011 11h53 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 9, 2011) - The cost of running a comparative effectiveness trial is $13,087 per patient during Phase IV, according to a study by Cutting Edge...